Deadline Boosts Colorectal Cancer Screening Uptake in TEMPO Trial

By João L. Carapinha

March 17, 2025

Are deadlines the secret to increasing colorectal cancer screening rates? The TEMPO trial, a nationwide randomized controlled trial in Scotland, evaluated the impact of two behavioral interventions on colorectal cancer screening uptake. These interventions included adding a deadline for returning faecal immunochemical tests (FIT) and using a problem-solving planning tool. The study found that including a deadline in the invitation letter significantly increased timely FIT returns and reduced the need for reminder letters. The planning tool had no positive effect. A 2-week deadline was identified as the most effective and acceptable option.

Key Insights from the TEMPO Trial

  • Deadline Effectiveness. Adding a deadline to the FIT invitation letter increased timely returns and reduced the need for reminder letters. The 2-week deadline was particularly effective in enhancing colorectal cancer screening rates.
  • Planning Tool Ineffectiveness. The planning tool did not improve FIT return rates and was even detrimental when used without a deadline.
  • Cost-Effectiveness. The deadline intervention is highly cost-effective, requiring minimal additional resources.

Understanding the Colorectal Screening Landscape

Colorectal cancer screening uptake is suboptimal globally, with about 50% participation in European FIT programs. Interventions like deadlines and planning tools could enhance participation. The TEMPO trial is the first to assess these interventions within a nationwide screening program.

Strategic Implications and Future Directions

Implementing deadlines could increase FIT returns and potentially save lives by facilitating earlier detection of colorectal cancer. Reducing reminder letters can lead to substantial cost savings for screening programs. Further studies should explore the effectiveness of deadlines in other screening contexts. They should also assess potential barriers to implementation, such as literacy levels and language barriers. For more insights into the effectiveness of these interventions, you can explore the article on The Lancet’s website here.

Reference url

Recent Posts

Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung Cancer

By HEOR Staff Writer

April 15, 2026

The FDA’s Priority Review of ifinatamab deruxtecan was recently announced, a potential first-in-class B7-H3 targeted therapy. The Biologics License Application for ifinatamab deruxtecan (I-DXd), a B7-H3 directed DXd antibody drug conjugate (ADC), has been accepted with a Prescription Drug User Fe...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability
In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes Treatment

By João L. Carapinha

April 14, 2026

The U.S. Food and Drug Administration has issued the generic dapagliflozin approval, clearing the first generic versions of FARXIGA (dapagliflozin) tablets. This decision significantly improves affordability and access to an important SGLT2 inhibitor for adults with type 2 diabetes. ...